Summary

On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic, and the disease now affects nearly every country and region. Caused by SARS-CoV-2, COVID-19 continues nearly 18 months later to present significant challenges to health systems and public health in both hemispheres, as well as the economies of every country. The morbidity and mortality of the infection caused by SARS-CoV-2 has been significant, and various waves of disease outbreaks initially overwhelmed many hospitals and clinics and continue to do so in many countries. This influences everyone, and public health countermeasures have been dramatic in terms of their impact on employment, social systems, and mental health. This entry collection aims to gather diverse fields about COVID-19, including in epidemiology, public health, medicine, genetics, systems biology, informatics, data science, engineering, sociology, anthropology, nursing, environmental studies, statistics, and psychology.

Expand All
Entries
Topic Review
COVID-19 Inflammation and Blood Coagulation Biomarkers
In general, an individual who experiences the symptoms of Severe Acute Respiratory Syndrome Coronavirus 2 or SARS-CoV-2 infection is declared as recovered after 2 weeks. However, approximately 10–20% of these survivors have been reported to encounter long-term health problems, defined as ‘long COVID-19’, e.g., blood coagulation which leads to stroke with an estimated incidence of 3%, and pulmonary embolism with 5% incidence. At the time of infection, the immune response produces pro-inflammatory cytokines that stimulate stromal cells to produce pro-hepatocyte growth factor (pro-HGF) and eventually is activated into hepatocyte growth factor (HGF), which helps the coagulation process in endothelial and epithelial cells. HGF is a marker that appears as an inflammatory response that leads to coagulation.
  • 483
  • 20 Jul 2023
Topic Review
Drugs Repurposed against SARS CoV-2 Drug Targets
Drug repurposing is a process to identify new roles for existing drugs and is generally considered an efficient and economical approach. Repurposing—also known as re-profiling, re-tasking, repositioning, and rescue of drugs—can help identify new therapies for diseases, at a lower cost and in a shorter time.
  • 538
  • 14 Jul 2023
Topic Review
The Interaction between Pregnancy and COVID-19
Pregnancy does not increase susceptibility to SARS-CoV-2 infection but appears to worsen the clinical course of COVID-19 (e.g., increased risks of intensive care unit [ICU] admission, need for mechanical ventilation and ventilatory support, and death) compared with non-pregnant females of the same age, especially in those who are symptomatic.  The risk of an exacerbation is greatest in the third trimester. Other risk factors associated with being infected and hospitalised with COVID-19 include Black and Asian minority ethnic backgrounds, living in socioeconomically deprived areas, and working in healthcare or other public-facing occupations
  • 608
  • 11 Jul 2023
Topic Review
Pharmaceutical Communication in Spain during COVID-19
This research addresses the scientific production of pharmaceutical communication in Spain around the COVID-19 crisis, in which information overload, amplified by the digital media, evidenced the relevance of communication in the digital society.
  • 541
  • 07 Jul 2023
Topic Review
Infection and Inflammation Interplay in Pediatric Long COVID
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents has generated repercussions, especially a few weeks after infection, for symptomatic patients who tested positive, for asymptomatic ones, or even just the contacts of an infected person, and evolved from severe forms such as multisystem inflammatory syndrome in children (MIS-C) to multifarious clinical manifestations in long COVID (LC). Referred to under the umbrella term LC, the onset of persistent and highly heterogeneous symptoms such as fatigue, post-exertion malaise, cognitive dysfunction, and others have a major impact on the child’s daily quality of life for months. 
  • 557
  • 06 Jul 2023
Topic Review
Current Regulation of Anti-COVID-19 mRNAs
COVID-19 vaccines were developed and approved rapidly in response to the urgency created by the pandemic. No specific regulations existed at the time they were marketed. The regulatory agencies therefore adapted them as a matter of urgency. Now that the pandemic emergency has passed, it is time to consider the safety issues associated with this rapid approval. The mode of action of COVID-19 mRNA vaccines should classify them as gene therapy products (GTPs), but they have been excluded by regulatory agencies.
  • 1.0K
  • 27 Jun 2023
Topic Review
Diagnosis of Heart Failure in Patients after COVID-19
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can lead to myocardial damage. Heart failure (HF) is a significant global health concern and is characterized as a clinical syndrome with symptoms caused by structural and/or functional abnormalities of the heart, confirmed by elevated natriuretic peptide levels and evidence of pulmonary or systemic congestion. The relationship between COVID-19 and heart failure is complex. SARS-CoV-2 can cause cardiac damage through the activation of pro-inflammatory cytokines. Understanding the interactions between the disease and viruses is crucial for optimal patient care. However, the validity of screening for cardiovascular complications after COVID-19 remains unconfirmed, and individualized diagnosis procedures are necessary based on the patient's clinical symptoms.
  • 555
  • 19 Jun 2023
Topic Review
Microbial Pathogens in Action after COVID Pandemic
The COVID-19 pandemic impacted the unique means for prompting the scientific community to consider developing healthcare infrastructures and logistics that will deal with any future pandemics, maybe in a manner comparable to dealing with biological war or an outside attack due to Manmade weapons. Biomedical experts have refocused their efforts on creating innovative vaccines and medicines to halt the deadly spread of these infections using new biological approaches. Only a small number of innovative nations have a healthy security policy on national level in the event of a biological attack that has been bio-weaponized by a human. After Covid pandemic, It is assumed that the whole world may have a fight against Multiple resistant bacterial pathogens or microorganism connected to water and food. MDR bacteria (like MRSA and VRSA) in addition to newly mutated microorganism may also infect human beings, birds and animals. 
  • 539
  • 19 Jun 2023
Topic Review
Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination
Virus-derived nucleic acids are potential immune-enhancers and particularly good candidates as adjuvants in vaccines in mouse models. The most important nucleic-acid-sensing process involves the dendritic cell (DC) Toll-like receptor (TLR), which participates in the pattern recognition of foreign DNA/RNA structures. Human CD141+ DCs preferentially express TLR3 in endosomes and recognize double-stranded RNA. Antigen cross-presentation occurs preferentially in this subset of DCs (cDCs) via the TLR3–TICAM-1–IRF3 axis. Another subset, plasmacytoid DCs (pDCs), specifically expresses TLR7/9 in endosomes.
  • 468
  • 19 Jun 2023
Topic Review
Impact of Hesitancy on Cancer Care and COVID-19
The COVID-19 pandemic disrupted the optimal management of outpatient appointments, scheduled treatments, and hospitalizations for cancer patients because of hesitancy among patients and health-care providers. Travel restrictions and other factors likely affected medical, surgical, and radiation treatments during the COVID-19 pandemic. Cancer patients were more likely to be affected by severe illness and complications if they contracted COVID-19. A compromised immune system and comorbidities in cancer patients may have contributed to this increased risk. Hesitancy or reluctance to receive appropriate therapy or vaccination advice might have played a major role for cancer patients, resulting in health-care deficits. 
  • 627
  • 16 Jun 2023
  • Page
  • of
  • 74

Other Entry Collections

>>